PFE heads into Q4 earnings with strong oncology and Vyndaqel demand, but IRA headwinds, COVID declines and falling estimates ...

Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the ...

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...

Add Yahoo as a preferred source to see more of our stories on Google. A vial of the Pfizer/BioNTech Comirnaty vaccine against Covid-19 at a mass vaccination center on July 1, 2021 in Leipzig, Germany.

Albert Bourla admitted to going to extreme lengths to “save the world” and get the vaccines out faster during the COVID-19 ...

Pfizer and BioNTech report that their updated mRNA COVID-19 vaccine for the 2025–2026 season produced strong immune responses, boosting neutralizing antibody levels by at least fourfold in older ...

Also: All the news and watercooler chat from Fortune.

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) reported topline Phase 3 results for their LP.8.1-adapted monovalent COMIRNATY (2025-2026 Formula) in high-risk adults. Among 100 participants, the ...

New York-based Pfizer Inc. (PFE) is a leading global biopharmaceutical company. With a market cap of $139.3 billion, it is ...

The US Food and Drug Administration has issued emergency use authorization (EUA) for the Covid-19 vaccine developed by Pfizer and BioNTech. After months of development, emergency use was authorized ...

FRANKFURT (Reuters) - Moderna and Pfizer-BioNTech are in a tight race to launch their COVID-19 vaccines in Europe after both applied for emergency EU approval on Tuesday, though there was uncertainty ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual property developed by Monsanto, the crop science company the German company ...